11.01.03
Unigen Pharmaceuticals has unveiled its three newest products. Lasoperin is a new product that is meant to offer short-term nutritional support for attention and focus, and long-term support of cognition and memory. In a recent randomized, double-blind, placebo-controlled trial, the company claimed that Lasoperin demonstrated statistically significant effects on memory, attention, focus and speed of processing. Unigen has also introduced a proprietary policosanol compound to ameliorate conditions involved with a number of health concerns for which the company has filed patents, including obesity, syndrome X, diabetes, hypercholesterolemia, atherosclerotic complications, ischemia and thrombosis. This compound, which is derived from Cera chinensis, was recently allowed a U.S. patent for composition of matter, as well as its extraction process. Unigen’s policosanol will soon be named in line with the company’s branding strategy. Lastly, the company has launched DiAfin™, a non-stimulant botanical weight loss product, which provides a combination of plant extracts that affect fructose metabolism and maintain anti-inflammatory properties.